Company: ARMP
Filing Date: 2025-08-13
Form Type: S-3
Source: 0001104659-25-077648
Chunk: 6

Company: Armata Pharmaceuticals, Inc.
Filing Date: 2025-08-13
Form: S-3
Chunk 6
---
 bacterial resistance to current classes of antibiotics. Bacteriophages or “phages”
have a powerful and highly differentiated mechanism of action that enables binding to and killing of specific targeted bacteria while
uniquely preserving the normal human microbiome or “healthy bacteria”. This is in direct contrast to traditional broad-spectrum
antibiotics which can alter the human microbiome increasing susceptibility to opportunistic pathogens, such as Clostridium difficile.
We believe that phages represent a promising means to effectively treat bacterial infections as an alternative to broad-spectrum antibiotics,
especially for patients with bacterial infections resistant to current standard of care therapies, including the multidrug-resistant or
“superbug” strains of bacteria. We are a leading developer of clinical-stage phage therapeutics of high purity, and believe
we are uniquely positioned to address the growing worldwide threat of antibiotic-resistant bacterial infections.

We
are combining our proprietary approach and expertise in identifying, characterizing and developing both naturally occurring and engineered
(synthetic) bacteriophages with our proprietary phage-specific host-engineered current Good Manufacturing Practices (“cGMP”)
manufacturing capabilities to advance a target pipeline of high-quality bacteriophage product candidates for late-stage clinical development.
Our optimized manufacturing processes significantly increase phage titers and improve production efficiency with the goal of ensuring
commercial viability.

We
remain committed to our mission to evaluate phage-based therapeutics in randomized controlled clinical trials that evaluate safety and
efficacy required to support potential regulatory approval and commercialization of our phage products as alternatives to traditional
antibiotics, providing a potential method of treating patients suffering from drug-resistant and difficult-to-treat bacterial infections.
To date, we have completed three critical Phase 2 trials, utilizing two distinct phage cocktails against two different bacterial pathogens
with the potential to treat chronic pulmonary disease complicated by bacterial infection, as well as acute systemic bacterial infection.
We believe that we are uniquely advancing our two lead candidates, referred to as AP-PA02 and AP-SA02, to address both chronic and acute
bacterial infections.

Pseudomonas aeruginosa Phage Product Candidate, AP-PA02

Clinical Development of AP-PA02 in Cystic Fibrosis: Completed Phase 1b/2a Study

Our
first phage candidate, inhaled AP-PA02, is focused primarily on the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa (“P. aeruginosa”). On October 14, 2020, we received